{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '490 Lapp Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.42,
 'askSize': 1400,
 'averageDailyVolume10Day': 383250,
 'averageVolume': 880111,
 'averageVolume10days': 383250,
 'beta': None,
 'beta3Year': None,
 'bid': 3.3,
 'bidSize': 1400,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Malvern',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.42,
 'dayLow': 3.27,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.654,
 'enterpriseToRevenue': None,
 'enterpriseValue': 20365960,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '484 395 2471',
 'fiftyDayAverage': 3.7802858,
 'fiftyTwoWeekHigh': 10.14,
 'fiftyTwoWeekLow': 2.16,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11863256,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 24,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01679,
 'heldPercentInstitutions': 1.16039,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/baudaxbio.com',
 'longBusinessSummary': 'Baudax Bio, Inc., a pharmaceutical company, develops '
                        'and commercializes products for hospital and other '
                        'acute care settings. Its lead product candidate is '
                        'intravenous form of meloxicam, a non-opioid that has '
                        'completed Phase III clinical trials for the '
                        'management of moderate to severe pain; and is in the '
                        'Phase IIIb clinical trials in colorectal surgery and '
                        'orthopedic surgery patients to assess opioid '
                        'consumption, pain intensity, and length of hospital '
                        'stay with associated pharmacoeconomic parameters. The '
                        "company's early-stage product candidates includes "
                        'RP1000, an intermediate-acting neuromuscular blocking '
                        'agent (NMBA) that is in phase I clinical trial; and '
                        'RP2000, an ultrashort-acting NMBA, which is in '
                        'pre-clinical trial; and a reversal agent, as well as '
                        'Dex-IN, a proprietary intranasal formulation of '
                        'dexmedetomidine. The company was incorporated in 2019 '
                        'and is based in Malvern, Pennsylvania.',
 'longName': 'Baudax Bio, Inc.',
 'market': 'us_market',
 'marketCap': 57981000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_643015818',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68520000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.3,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '484 395 2440',
 'previousClose': 3.36,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.42,
 'regularMarketDayLow': 3.27,
 'regularMarketOpen': 3.3,
 'regularMarketPreviousClose': 3.36,
 'regularMarketPrice': 3.3,
 'regularMarketVolume': 518005,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17570000,
 'sharesPercentSharesOut': 0.1475,
 'sharesShort': 2591038,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2364703,
 'shortName': 'Baudax Bio, Inc.',
 'shortPercentOfFloat': 0.1618,
 'shortRatio': 2.92,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'BXRX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 4.854885,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'f572c510-1f7d-360f-9b4e-fc4abd8f4366',
 'volume': 518005,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.baudaxbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19355'}